

Claims

1. A cosmetic method for improving and/or maintaining the skin tone of an individual, said method comprising contacting the skin of said individual with a composition comprising at least one ACE inhibitor and/or angiotensin II receptor antagonist, or a cosmeceutically acceptable salt thereof.
5
2. The cosmetic method according to the preceding claim, wherein said ACE inhibitor and/or angiotensin II receptor antagonist is selected from Alacepril, Delapril Benazepril, Cilazapril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Ramipril, Quinapril, Trandolapril, Imidapril, Isradipin, perindopril, spirapril, temocapril, Enalapril, losartan (Cozaar), valsartan (Diovan), irbesartan (Avapro), candesartan (Atacand), telmisartan (Micardis), eprosartan, tasosartan, zolarsartan, Zofenapril, Isradipin and Candesartancilexetil, or a cosmeceutically acceptable salt thereof.
10
15
3. The cosmetic method according to any of the preceding claims, wherein said ACE inhibitor and/or angiotensin II receptor antagonist is selected from Alacepril, Delapril, Cilazapril, Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Ramipril, Quinapril, Trandolapril, Imidapril, Isradipin, perindopril, spirapril, temocapril, Enalapril, Zofenapril, or a cosmeceutically acceptable salt thereof.
20
4. The cosmetic method according to any of the preceding claims, wherein said ACE inhibitor or angiotensin II receptor antagonist is selected from losartan (Cozaar), valsartan (Diovan), irbesartan (Avapro), candesartan (Atacand), telmisartan (Micardis), eprosartan, tasosartan, zolarsartan, Isradipin, Candesartancilexetil and/or olmesartan medoxomil, or a cosmeceutically acceptable salt thereof.
25
30
5. The cosmetic method according to any of the preceding claims, wherein said ACE inhibitor is lisinopril, or a cosmeceutically acceptable salt thereof.

6. The cosmetic method according to any of the preceding claims, wherein said composition comprises at least two ACE inhibitor(s) and/or angiotensin II receptor antagonist(s).
- 5 7. The cosmetic method according to any of the preceding claims, wherein said ACE inhibitor or angiotensin II receptor antagonist is present in said compositions in an amount between about 0.01-100 mg/kg.
- 10 8. The cosmetic method according to any of the preceding claims, wherein said ACE inhibitor or angiotensin II receptor antagonist is present in said composition in an amount between about 0.1-10 mg/kg.
- 15 9. The cosmetic method according to any of the preceding claims, wherein said composition further comprises a cosmeceutically-acceptable topical carrier.
- 20 10. The cosmetic method according to any of the preceding claims, wherein said cosmetic method further comprises one or more of a hormone, plant and/or herbal extracts, moisturizers or humectants, emollients, fragrances, sun-screen actives, anti-wrinkle and/or anti-ageing actives, whitening and/or bleaching actives, sunless tanning actives, preservative and/or antimicrobial actives, anti-acne actives, anti-psoriasis actives, anti-eczema actives, anti-inflammatory actives, vitamin actives, proteins, peptides, amino acids, amino acid derivatives, insect repellants, fungicides, anti-viral agents, anti-cancer agents, anti-hemorrhoid compounds, anti-dandruff compounds, hair-growth stimulating compounds, hair-loss stimulating compounds, nucleic acids, chelating agents, pigments, lipids and/or inorganic salts.
- 25 11. The cosmetic method according to any of the preceding claims, wherein said composition further comprises one or more of a hydroxy acid, lactic acid, 2-hydroxy butanoic acid, malic acid, citric acid tartaric acid, decorin-synthesis enhancers, retinoids which include retinol and its esters, retinal, retinoic acid and its derivatives, retinoids, an alpha-hydroxy acid, a beta-hydroxy acid, an alpha-keto acids, a beta-keto acid, a peroxide, a vitamin, an anti-free-radical active agents, selenium, zinc, a beta-carotene, tensioning polymers of natural or synthetic origin, collagen-synthesis enhancers, a matrix metallopro-
- 30
- 35

5 teinase inhibitor, an antioxidant, a collagen modulator, an alpha-hydroxyethanoic acid, a hydroxycaprylic acid; an alpha-hydroxycarboxylic acid, beta-hydroxycarboxylic acid, a ceramide, a polyhydroxy acid, gamma-linolenic acid, a fruit acid, sugar cane extract, a skin peel agent, or a cosmetically-acceptable salt thereof.

10 12. The cosmetic method according to any of the preceding claims, wherein said composition is formulated as one or more of: a day and/or night and/or hydrating care composition for the face or the body; an anti-wrinkle or anti-ageing composition; a make-up removing composition; a body milk, a sun protective, artificial sun tanning (self-tanning) or after-sun care composition; and/or a face, skin, body or lip makeup product;

15 13. The cosmetic method according to any of the preceding claims, wherein said composition is formulated in any suitable manner for application to an individual's skin.

20 14. The cosmetic method according to any of the preceding claims, wherein said composition is formulated as a lotion, cream, face mask, powder, cosmetic patch, ointment, paste, water-based liquid, oil-based liquid or sprayable liquid.

25 15. The cosmetic method according to any of the preceding claims, wherein said composition is formulated as a cream or lotion.

16. The cosmetic method according to claim 15, wherein said method for improvement and/or maintenance of skin tone comprises prevention or reduction of skin ageing and/or wrinkling.

30 17. The method according to any of claims 15-16 wherein said contacting is conducted at least once daily.

35 18. The method according to any of the claims 15-17 wherein said method further comprises contacting the skin with one or more hormones, plant and/or herbal extracts, moisturizers or humectants, emollients, fragrances, sun-

screen actives, anti-wrinkle and/or anti-ageing actives, whitening and/or bleaching actives, sunless tanning actives, preservative and/or antimicrobial actives, anti-acne actives, anti-psoriasis actives, anti-eczema actives, anti-inflammatory actives, vitamin actives, proteins, peptides, amino acids, amino acid derivatives, insect repellants, fungicides, anti-viral agents, anti-cancer agents, anti-hemorrhoid compounds, anti-dandruff compounds, hair-growth stimulating compounds, hair-loss stimulating compounds, nucleic acids, chelating agents, pigments, lipids and/or inorganic salts.

- 5
- 10 19. The method according to any of claims 15-18 wherein said individual is a post-menopausal, female human being.
- 15 20. The method according to any of claims 15-18 wherein said individual is a pre-menopausal, female human being.
- 20 21. The method according to any of claims 15-18 wherein said individual is a male human being.
22. The method according to any of claims 15-21 which comprises repeatedly performing said contacting over an extended period of time.
- 25 23. Use of an ACE inhibitor and/or angiotensin II receptor antagonist for the preparation of a medicament for the treatment of skin ageing or wrinkling.
24. The use according to claim 23, wherein said skin ageing or wrinkling is considered premature as compared to normal skin ageing and wrinkling.
- 30 25. The use according to claim 24 wherein said skin ageing or wrinkling is caused by, or associated with, diabetes mellitus.
26. The use according to claims 24 wherein said skin ageing or wrinkling is caused by, or associated with, smoking or smoke exposure on skin
- 35 27. The use according to claim 24, wherein said skin ageing or wrinkling is caused by skin photo-ageing processes.

28. The use according to claim 24, wherein said skin ageing or wrinkling is caused by, or associated with, radiation therapy.
- 5 29. The use according to claim 24, wherein said skin ageing or wrinkling is caused by, or associated with, syndrome X.
30. The use according to claim 24, wherein said skin ageing or wrinkling is caused by, or associated with, Hutchinson-Gilford progeria.
- 10 31. The use according to claim 24, wherein said skin ageing or wrinkling is caused by, or associated with, Werners syndrome
32. The use according to claim 24, wherein said skin ageing or wrinkling is caused by, or associated with, Kindler syndrome.
- 15 33. The use according to claim 24, wherein said skin ageing or wrinkling is caused by, or associated with, corticoid hormone hypersecretion, a vitamin deficiency, administration of glucocorticoids and/or vitamin D and/or derivatives thereof.
- 20 34. The use according to any of claims 23-33, wherein the medicament comprises an ACE inhibitor or angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof.
- 25 35. The use according to any claims 23-34 wherein the ACE inhibitor and/or angiotensin II receptor antagonist is according to any of claims 2-6
- 30 36. The use according to any of claims 23-35, wherein the medicament is in a formulation for topical administration to the skin
- 35 37. The use according to any of claims 23-36 wherein the ACE inhibitor/angiotensin II receptor antagonist is formulated as a lotion, powder, cream, ointment, water-based liquid, paste, oil-based liquid, face mask, skin patch or sprayable liquid.

38. The use according to any of claims 23-37 in combination with one or more of a hormones, a plant and/or herbal extracts, a moisturizers or humectants, an emollients, a fragrances, a sunscreen actives, an anti-wrinkle and/or anti-ageing actives, a whitening and/or bleaching actives, a sunless tanning actives, a preservative and/or antimicrobial actives, an anti-acne actives, an anti-psoriasis actives, an anti-eczema actives, an anti-inflammatory actives, a vitamin active, a protein, a peptide, an amino acid, an amino acid derivative, an insect repellants, a fungicide, an anti-viral agent, an anti-cancer agent, an anti-hemorrhoid compound, an anti-dandruff compound, a hair-growth stimulating compound, a hair-loss stimulating compound, a nucleic acid, a chelating agents, a pigment, a lipid and/or an inorganic salts.
39. The use according to any of claims 23-38, wherein the medicament is administered at least once daily
40. The use according to any of claims 23-39, wherein the medicament is administered at least two times daily.
41. The use according to any of claims 23-40, wherein the medicament is administered in a concentration equivalent of from 0.01 to 100 mg per kg.
42. The use according to any of claims 23-41, wherein the medicament is administered in a concentration equivalent of from 0.1 to 10 mg per kg.
43. Use of an ACE inhibitor and/or angiotensin II receptor antagonist for the preparation of a cosmetic composition for the improvement and/or maintenance of skin tone.
44. The use according to claim 43, wherein said improvement and/or maintenance of skin tone comprises prevention and/or reduction of skin ageing and/or wrinkling.
45. The use according to claims 43-44, wherein said ACE inhibitor and/or angiotensin II receptor antagonist is according to any of claims 2-6

46. The use according to any of claims 43-45, wherein said composition comprises more than one ACE inhibitor or angiotensin II receptor antagonist or a cosmeceutically acceptable salt thereof.

5

47. The use according to any of claims 43-46 wherein said ACE inhibitor or angiotensin II receptor antagonist is present in an amount according to any of claims 7-8.

10

48. The use according to any of claims 43-47, wherein said cosmetic composition is formulated in a manner according to any of claims 9-15.